Advanced Oncotherapy Plc is focused on providing radiotherapy systems for cancer treatment through the use of a proton therapy technology. The Company is engaged in development and then building of the Linac Image Guided Hadron Technology (LIGHT) proton beam cancer therapy device and management of healthcare related property. The Company's segments include Development of Proton Therapy-UK; Development of Proton Therapy-Switzerland; Development of Proton Therapy-USA, and Healthcare-related properties-UK. Its LIGHT system uses accelerators, which is a series of modular units. This feature offers hospitals and centers to customize treatment plans based on a range of energies. The Company's Research and development/ADAM S.A. (R&D/ADAM) facility is located on the campus of European Council for Nuclear Research (CERN), Geneva, Switzerland, and a manufacturing plant, clinical research and clinician training facility in Syracuse, the United States.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Advanced Medical Equipment & Technology - NEC
- Sub-Industry: N/A
- Symbol: LON:AVO
- CUSIP: N/A
- Web: www.advancedoncotherapy.com/
- Market Cap: £11.41 million
- Outstanding Shares: 72,467,000
- 50 Day Moving Avg: GBX 15.13
- 200 Day Moving Avg: GBX 36.76
- 52 Week Range: GBX 11 - GBX 149
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: GBX 0.47 per share
- Price / Book: 0.34
- EBIDTA: ($12,740,000.00)
- Return on Equity: -31.23%
- Return on Assets: -26.68%
- Average Volume: 413,347 shs.
Frequently Asked Questions for Advanced Oncotherapy PLC (LON:AVO)
What is Advanced Oncotherapy PLC's stock symbol?
Advanced Oncotherapy PLC trades on the London Stock Exchange (LON) under the ticker symbol "AVO."
Who are some of Advanced Oncotherapy PLC's key competitors?
Some companies that are related to Advanced Oncotherapy PLC include Xtant Medical Holdings (XTNT), Sphere Medical Holding PLC (SPHR), PhotoMedex (PHMD), Dextera Surgical (DXTR), BIOLASE (BLTI), Cynosure (CYNO), Derma Sciences (DSCI), Hansen Medical (HNSN), Lifeline Scientific (LSIC), Mindray Medical International Ltd (MR), Nanosphere (NSPH), Sirona Dental Systems (SIRO), Synergetics USA (SURG), Thoratec (THOR), Volcano Corp (VOLC) and Zeltiq Aesthetics (ZLTQ).
Who are Advanced Oncotherapy PLC's key executives?
Advanced Oncotherapy PLC's management team includes the folowing people:
- Michael J. Sinclair, Executive Chairman of the Board
- Nicolas Serandour, Chief Executive Officer, Executive Director
- Sanjeev Pandya, Executive Vice President - Global Business Development, Executive Director
- Richard Amos, Director of Medical Physics
- Michel Baelen, Head of Regulatory Affairs
- Gerardo DAuria, Technical Director
- Michael R. Graham, Global Head of QMS and Product Realisation
- Donatella Ungaro, ADAM Managing Director Based at CERN
- Michael Bradfield, Non-Executive Director
- Steve Myers, Non-Executive Director
How do I buy Advanced Oncotherapy PLC stock?
Shares of Advanced Oncotherapy PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Advanced Oncotherapy PLC's stock price today?
MarketBeat Community Rating for Advanced Oncotherapy PLC (LON AVO)MarketBeat's community ratings are surveys of what our community members think about Advanced Oncotherapy PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Advanced Oncotherapy PLC stock can currently be purchased for approximately GBX 15.75.
Consensus Ratings for Advanced Oncotherapy PLC (LON:AVO) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Advanced Oncotherapy PLC (LON:AVO)
(Data available from 7/25/2015 forward)
Earnings History for Advanced Oncotherapy PLC (LON:AVO)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Advanced Oncotherapy PLC (LON:AVO)
Current Year EPS Consensus Estimate: $-6.71 EPS
Dividend History for Advanced Oncotherapy PLC (LON:AVO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Advanced Oncotherapy PLC (LON:AVO)Insider Trades by Quarter for Advanced Oncotherapy PLC (LON:AVO)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/15/2017||Steve Myers OBE||Insider||Buy||400,000||GBX 26||£104,000|
|5/9/2017||Christopher Nutting||Insider||Buy||202,500||GBX 25||£50,625|
|4/25/2017||Michael J Sinclair||Insider||Buy||200,000||GBX 30||£60,000|
|4/24/2017||Enrico Cipro Vanni||Insider||Buy||100,000||GBX 27||£27,000|
|4/12/2017||Enrico Cipro Vanni||Insider||Buy||100,000||GBX 28||£28,000|
|4/4/2017||Enrico Cipro Vanni||Insider||Buy||25,000||GBX 29||£7,250|
|4/3/2017||Michael J Sinclair||Insider||Buy||100,000||GBX 28||£28,000|
|1/3/2017||Enrico Cipro Vanni||Insider||Buy||25,000||GBX 87||£21,750|
|12/29/2016||Enrico Cipro Vanni||Insider||Buy||25,000||GBX 66||£16,500|
|12/22/2016||Enrico Cipro Vanni||Insider||Buy||25,000||GBX 60||£15,000|
|12/20/2016||Enrico Cipro Vanni||Insider||Buy||25,000||GBX 55||£13,750|
|12/19/2016||Enrico Cipro Vanni||Insider||Buy||25,000||GBX 50||£12,500|
|7/11/2016||Bradfield ,Michael||Insider||Buy||30,000||GBX 135||£40,500|
|7/8/2016||Bradfield ,Michael||Insider||Buy||10,000||GBX 120||£12,000|
|7/7/2016||Bradfield ,Michael||Insider||Buy||10,000||GBX 112||£11,200|
|7/6/2016||Bradfield ,Michael||Insider||Buy||50,000||GBX 102||£51,000|
|12/18/2015||Bradfield ,Michael||Insider||Buy||750,000||GBX 7||£52,500|
|12/17/2015||Bradfield ,Michael||Insider||Buy||1,000,000||GBX 6||£60,000|
|12/16/2015||Bradfield ,Michael||Insider||Buy||750,000||GBX 6||£45,000|
|7/20/2015||Vanni ,Enrico Cipro||Insider||Buy||1,000,000||GBX 8||£80,000|
|7/1/2015||Sinclair,Michael J||Insider||Sell||7,000,000||GBX 0.08||£5,600|
|6/5/2015||Michael Bradfield||Insider||Buy||1,500,000||GBX 9.81||£147,150|
|2/4/2015||Michael Bradfield||Insider||Buy||500,000||GBX 4.10||£20,500|
Headline Trends for Advanced Oncotherapy PLC (LON:AVO)
Latest Headlines for Advanced Oncotherapy PLC (LON:AVO)
Advanced Oncotherapy PLC (AVO) Chart for Tuesday, July, 25, 2017